
Rapid and Accurate AAV Capsid Quantification Using Multi-Angle Dynamic Light Scattering (MADLS) for In-Process Gene Therapy Manufacturing
简介:
- 作者: T. Pan
- 杂志: Cytotherapy
- Doi: https://www.doi.org/10.1016/j.jcyt.2025.03.454
- 出版日期: 2025-05-01
摘要
Background & Aim: Adeno-associated viruses (AAVs) are widely utilized as vectors for gene delivery in therapeutic applications. Precise quantification of AAV capsid titers is crucial for ensuring consistent product quality and safety during manufacturing. Current methods such as ELISA, while effective, are time-consuming and involve multiple steps, including incubation and washing, which may limit their suitability for quick paced in-process sample testing.Methodology: We conducted a study to evaluate Multi-Angle Dynamic Light Scattering (MADLS) as a rapid and reliable alternative method for measuring AAV capsid titer, particle size, and aggregation. Unlike ELISA, the MADLS assay is a one-step process that requires no sample manipulation and yields results in under 10 minutes. This feature makes MADLS particularly suitable for real-time, in-process testing, enabling faster decision-making during AAV manufacturing. Results: Our findings show that MADLS provides results comparable to ELISA in terms of accuracy, while significantly reducing the time required for analysis. The method's capability to perform repeated measurements without time constraints further enhances its utility in ensuring consistent product quality across multiple stages of the production workflow. Additionally, MADLS eliminates the need for complex sample preparation, thereby reducing the potential for operator-induced variability. Conclusion: The adoption of MADLS in AAV manufacturing reflects the growing need for fast, precise, and simple nanoparticle characterization in gene therapy, pharmaceuticals, and medical applications. streamlining key analytical processes, MADLS enhances manufacturing efficiency, accelerates production timelines, improves process control, and ensures consistent product quality, ultimately enabling the faster delivery of high-quality gene therapy products to meet patient needs.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
